Meloxicam Market Size & Share, by Diseases (Osteoarthritis, Rheumatoid Arthritis, Juvenile Rheumatoid Arthritis), Drug Type (Combination Drug, Prescribed Drug), Population Type (Adult, Children), Dosage (Oral, Parenteral, transdermal), Dose Strength (7.5mg, 15mg), End-Users (Hospitals, Specialty Clinics, Home Healthcare), Distribution Channel (Direct Tender, Hospital Pharmacy, Retail Pharmacy, Online Pharmacy) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2023-2036

  • Report ID: 5360
  • Published Date: Nov 02, 2023
  • Report Format: PDF, PPT

Global Market Size, Forecast, and Trend Highlights Over 2023-2036

Meloxicam Market size is anticipated to reach USD 47 billion by the end of 2036, expanding around 5% CAGR during the forecast period i.e., 2024-2036. In the year 2023, the industry size of meloxicam was over USD 7 billion. The growth of this market can be attributed to the back of increasing prevalence of osteoarthritis, juvenile rheumatoid arthritis, and rheumatoid arthritis especially among the old population. Meloxicam is an effective pain management medication highly used in the treatment of the above health problems. In this health issue when doctors initiate surgeries the post-surgery pain is always at a high range and is too much painful in order to offer relief from this pain to patients doctors use pain management medications such as meloxicam. Thus, the increasing incidence of these diseases is raising the demand for meloxicam market in the projected time period. As per a report by  the World Health Organization, 60% of those who have osteoarthritis are female and 73% are older than 55. The knee is the joint that is most frequently affected, with an estimated number of 365 million, next to the hip and the hand.   

Furthermore, the growth of the market can also be driven by increasing awareness about the availability of pain relief medication. In the past few times, there has been a surge in awareness about pain relief medication available in the market among the population. This is predicted to boost the market growth of meloxicam in the projection time period.

Meloxicam Market
Get more information on this report: Request Free Sample PDF

Meloxicam Sector: Growth Drivers and Challenges

Growth Drivers

  • Increasing Technological Advancement – The growth of this meloxicam market can be ascribed to an increasing technological advancement taking place in meloxicam. The global growth rate of the meloxicam retail market has been accelerated by the launch of new and enhanced goods as a result of the development of fresh technologies. Furthermore, advancements in drug delivery technologies and formulations are enhancing the efficacy and safety of meloxicam making it a more appealing treatment option.
  • Increasing Prevalence of NSAIDs - Increased preference for NSAIDs over other painkillers like opioids also contributes to the meloxicam market's expansion in the anticipated time period. NSAIDs such as meloxicam are at times preferred over other painkillers such as opioids owing to their lower risk of addiction and side effects. In addition, the meloxicam market is growing as chronic inflammation and pain illnesses become more prevalent.
  • Growing Strategic Collaboration and Partnerships – Pharmaceutical companies are collaborating with research institutions and other companies to develop new formulations and applications for meloxicam. Therefore, this is accelerating the market expansion of meloxicam in the upcoming time period. 


  • Competition from other NSAIDs – Meloxicam is one of many NSAIDs on the market, and it faces stiff competition from other drugs in its class, such as ibuprofen and naproxen. These drugs are often less expensive than meloxicam and may have a better safety profile. Therefore, high competition by other NSAIDs is expected to hamper the meloxicam market growth of meloxicam in the forthcoming years.
  • Concerns Associated with Side Effects of Meloxicam is Predicted to Restrict the Market Expansion in the Future Times
  • The Availability of Generic Meloxicam is Posing a Limitation on the Market Expansion in Forecast Period.

Meloxicam Market: Key Insights

Base Year


Forecast Year

2024 - 2036



Base Year Market Size

~USD 7 billion

Forecast Year Market Size

~USD 47 billion

Regional Scope

  • North America (U.S., and Canada)
  • Latin America (Mexico, Argentina, Rest of Latin America)
  • Asia-Pacific (Japan, China, India, Indonesia, Malaysia, Australia, Rest of Asia-Pacific)
  • Europe (U.K., Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe)
  • Middle East and Africa (Israel, GCC North Africa, South Africa, Rest of the Middle East and Africa)
Get more information on this report: Request Free Sample PDF

Meloxicam Segmentation

Diseases (Osteoarthritis, Rheumatoid Arthritis, Juvenile Rheumatoid Arthritis)

In terms of disease, the osteoarthritis segment in the meloxicam market is estimated to account for the largest revenue share of 40% by the end of 2036. The rise in prevalence and consumer awareness of treatment options like glucosamine and chondroitin sulfate, which do not significantly reduce the signs of this medical condition but instead assist in preserving joint motion over an extended period of time, can be attributed to the growth of this market in the projected time period. A severe health emergency also includes arthritis.  According to the CDC, 53.2 million US individuals, or 1 in 4, have some kind of arthritis. There are more than 100 different forms of arthritis, but osteoarthritis, which affects 32.5 million US adults, is the most widespread.

Drug Type (Combination Drug, Prescribed Drug)

Meloxicam market from the combination drug segment is set to grow significantly by 2036. Combination drugs are drugs taken together to treat different conditions, and their ability to treat many diseases is the main reason for this increase in demand. For example, Vioxx is a combination drug used to treat both rheumatoid arthritis and pain; however, it caused heart problems as well as other side effects and thus fell behind in the market.

Our in-depth analysis of the global meloxicam market includes the following segments:


  • Osteoarthritis
  • Rheumatoid Arthritis
  • Juvenile Rheumatoid Arthritis

          Drug Type

  • Combination Drug
  • Prescribed Drug

          Population Type

  • Adult
  • Children


  • Oral
  •  Parenteral
  • Transdermal

          Dose Strength

  • 7.5mg
  • 15mg


  • Hospitals
  •  Specialty Clinics
  • Home Healthcare

          Distribution Channel

  • Direct Tender
  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.

Customize this Report

Meloxicam Industry - Regional Synopsis

North American Market Forecasts

The meloxicam market in North America region is anticipated to account for the largest revenue share of 33% by the end of the forecast period. The growth of this market can be primarily driven by an increasing number of arthritis and other chronic pain disease patients found in this region. Besides, increasing healthcare infrastructure and escalating research and development activities in meloxicam are driving the market expansion further in the North America region during the projected period. An estimated 58.5 million US adults have been told by their doctor that they have some form of arthritis, rheumatoid arthritis, gout, lupus or fibromyalgia, based on data from the National Health Interview Survey between 2016 and 2018.

APAC Market Statistics

The meloxicam market in the Asia Pacific region is estimated to account for a notable revenue share during the forecast period. This growth can be attributed to high product demand due to the growing aging population and the increasing incidence of osteoarthritis, rheumatoid arthritis, soft tissue inflammation, traumatic pain and post-operative pain. Also, there has been surging demand for rheumatoid arthritis treatment in the region. Additionally, regional growth over the forecast period is expected to be driven by favorable reimbursement policies for generic drugs. All these factors are predicted to drive the market growth of meloxicam in the APAC region during the studied period.

Research Nester
Meloxicam Market Size
Get more information on this report: Request Free Sample PDF

Companies Dominating the Meloxicam Landscape

    • Taj Pharmaceutical Limited.
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Wellona Pharma
    • Trumac Healthcare
    • Healthy Life Pharma Private Limited.
    • Boehringer Ingelheim GmbH.
    • Baudax Bio
    • Heron Therapeutics Inc.
    • Avanstra Inc.
    • PD-Rx Pharmaceuticals, Inc.

In the News

  • Baudax Bio, Inc., a pharmaceutical company specializing in acute care therapies, announced that ANJESO (meloxicam), the only 24-hour intravenous COX-2 preferred nonsteroidal anti-inflammatory drug , is now available at command. and deliver goods to customers. ANJESO was approved by the U.S. Food and Drug Administration (FDA) on February 20, 2020, and is indicated for the treatment of moderate to severe pain, alone or in combination with other medications. Other non-NSAID pain relievers.
  • Heron Therapeutics, Inc., a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important needs of patients, today announced that the U.S. Food and Drug Administration (FDA) has approved ZYNRELEF (bupivacaine and meloxicam) extended-release solution for use in adults to soft tissue or periarticular drops to provide postoperative analgesia for up to 72 hours after bunionectomy, open inguinal hernia, and total knee replacement surgery.  

Author Credits:  Radhika Gupta, Shivam Bhutani

  • Report ID: 5360
  • Published Date: Nov 02, 2023
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

The growing prevalence of chronic pain disease and increasing research and development in meloxicam are some of the major factors anticipated to drive the growth of the meloxicam market.

The market is anticipated to attain a CAGR of ~5% over the forecast period, i.e., 2024-2036.

The major players in the market are of Healthy Life Pharma Private Limited., EPICON LIFESCIENCES LLP, Boehringer Ingelheim GmbH., Baudax Bio, Heron Therapeutics Inc., Avanstra Inc., PD-Rx Pharmaceuticals, Inc., and others.

The osteoarthritis segment is anticipated to garner the largest market size by the end of 2036 and display significant growth opportunities.

The market in North America is projected to hold the largest market share by the end of 2036 and provide more business opportunities in the future.
Meloxicam Market Report Scope

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying